TABLE 4.
OAC Use and Outcomes Over 3 Years in Patients With Prevalent AF and a Contraindication to OAC Use (n = 20,737)
| Event Rate Percentage at 3 Years* | Unadjusted | Adjusted† | ||||
|---|---|---|---|---|---|---|
| No OAC (n = 8,283) | OAC (n = 12,454) | p Value | HR (95% CI) | HR (95% CI) | p Value | |
| Death | 49.6 | 36.6 | <0.001 | 0.65 (0.63–0.68) | 0.79 (0.76–0.83) | <0.001 |
| Stroke-broad | 11.3 | 10.4 | 0.03 | 0.81 (0.74–0.88) | 0.90 (0.83–0.99) | 0.03 |
| Ischemic stroke | 6.04 | 5.18 | 0.01 | 0.76 (0.67–0.85) | 0.87 (0.77–0.98) | 0.03 |
| TIA | 2.74 | 2.53 | 0.36 | 0.82 (0.69–0.98) | 0.90 (0.75–1.07) | 0.23 |
| ICH | 2.03 | 2.84 | <0.001 | 1.26 (1.04–1.52) | 1.42 (1.17–1.72) | <0.001 |
| GI bleed-transfusion‡ | 0.99 | 1.33 | 0.03 | 1.20 (0.92–1.58) | 1.29 (0.98–1.70) | 0.08 |
| Hospitalization | 74.1 | 73.5 | <0.001 | 0.87 (0.84–0.89) | 0.93 (0.90–0.96) | <0.001 |
*
The death event rate p value is from the log-rank test. All other outcome event rate p values are from Gray’s tests.
†
Adjusted for age, race, gender, region, implantable device (ICD and cardiac resynchronization therapy with defibrillator), contraindication characteristics (number of contraindications, blood dyscrasia, ICH, and GI bleed), and comorbidities (atrial flutter, dementia, diabetes, coronary heart disease, peripheral vascular disease, congestive heart failure, cardiovascular disease, hypertension, COPD, renal disease, prior stroke, cancer, and valvular heart disease).
‡
Required a blood transfusion.